anastrozole has been researched along with Experimental Mammary Neoplasms in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fulvestrant has been studied as second line or first line treatment for post-menopausal hormone receptor positive breast cancers as a single agent or in combination with AIs." | 5.56 | Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity. ( Goloubeva, O; Kazi, A; Sabnis, GJ; Schech, A; Yu, S, 2020) |
| "These data support clinical investigation of anastrozole-AZD0530 therapy for postmenopausal ER-positive breast cancer." | 3.75 | Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. ( Chen, Y; Gonzalez-Angulo, A; Guggisberg, N; Hennessy, B; Jorda, M; Mills, GB; Slingerland, JM; Tan, CK, 2009) |
| "1 mg/kg, and the clearance half-life of 7-16 h indicated that once-daily dosing would be possible in humans." | 2.40 | The relevance of preclinical models to the treatment of postmenopausal breast cancer. ( Dukes, M, 1997) |
| "Fulvestrant has been studied as second line or first line treatment for post-menopausal hormone receptor positive breast cancers as a single agent or in combination with AIs." | 1.56 | Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity. ( Goloubeva, O; Kazi, A; Sabnis, GJ; Schech, A; Yu, S, 2020) |
| "Genistein could suppress the growth of mammary tumors in postmenopausal rats." | 1.40 | [Effect of genistein combined with anastrozole on mammary tumors in ovariectomized rats]. ( Kang, XM; Ma, WJ; Song, Y; Wang, L; Zhang, QY; Zhao, H, 2014) |
| "Letrozole was found to be a highly potent inhibitor of tumor proliferation and more effective than tamoxifen." | 1.30 | Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. ( Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, JP; Yue, W, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Kazi, A | 1 |
| Goloubeva, O | 1 |
| Schech, A | 1 |
| Yu, S | 1 |
| Sabnis, GJ | 1 |
| Lu, Y | 1 |
| You, M | 1 |
| Ghazoui, Z | 1 |
| Liu, P | 1 |
| Vedell, PT | 1 |
| Wen, W | 1 |
| Bode, AM | 1 |
| Grubbs, CJ | 1 |
| Lubet, RA | 1 |
| Wang, L | 1 |
| Kang, XM | 1 |
| Song, Y | 1 |
| Ma, WJ | 1 |
| Zhao, H | 1 |
| Zhang, QY | 1 |
| Sadlonova, V | 1 |
| Kubatka, P | 1 |
| Kajo, K | 1 |
| Ostatnikova, D | 1 |
| Nosalova, G | 1 |
| Adamicova, K | 1 |
| Sadlonova, J | 1 |
| Chen, Y | 1 |
| Guggisberg, N | 1 |
| Jorda, M | 1 |
| Gonzalez-Angulo, A | 1 |
| Hennessy, B | 1 |
| Mills, GB | 1 |
| Tan, CK | 1 |
| Slingerland, JM | 1 |
| Swami, S | 1 |
| Krishnan, AV | 1 |
| Wang, JY | 1 |
| Jensen, K | 1 |
| Peng, L | 1 |
| Albertelli, MA | 1 |
| Feldman, D | 1 |
| Tekmal, RR | 1 |
| Durgam, VR | 1 |
| Dukes, M | 1 |
| Brodie, A | 3 |
| Lu, Q | 3 |
| Liu, Y | 3 |
| Long, B | 2 |
| Wang, JP | 1 |
| Yue, W | 2 |
| Wang, J | 1 |
| Long, BJ | 1 |
| Grigoryev, D | 1 |
| Gimbel, M | 1 |
1 review available for anastrozole and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
The relevance of preclinical models to the treatment of postmenopausal breast cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase I | 1997 |
10 other studies available for anastrozole and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neopl | 2020 |
Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expres | 2013 |
[Effect of genistein combined with anastrozole on mammary tumors in ovariectomized rats].
Topics: 17-Hydroxysteroid Dehydrogenases; Anastrozole; Animals; Cell Line, Tumor; Cell Proliferation; Estrad | 2014 |
Side effects of anastrozole in the experimental pre-menopausal mammary carcinogenesis.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Female; | 2009 |
Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzodio | 2009 |
Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo.
Topics: Anastrozole; Animals; Aromatase; Aromatase Inhibitors; Calcitriol; Cell Line, Tumor; Cell Proliferat | 2011 |
A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminoglutethimide; Analysis of Variance; Anastrozole; Androstenedi | 1997 |
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1998 |
The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Enzyme Inhibitors; Estr | 1998 |
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Topics: Analysis of Variance; Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatas | 1999 |